Business Context and Reporting Period
Company: Prana Biotechnology Limited (ASX: PBT). Note: The request metadata references "Altery Therapeutics Ltd," but the filing text explicitly identifies the registrant as Prana Biotechnology Limited.
Filing Type: Form 6-K (Report of Foreign Private Issuer) / ASX Appendix 3B (New Issue Announcement).
Reporting Period: February 2014, specifically dated February 26, 2014.
Principal Executive Office: Level 2, 369 Royal Parade, Parkville, Victoria 3052, Australia.
Key Financial Metrics and Capital Structure
Capital Issuance:
- Securities Issued: 445,866 Ordinary Shares.
- Total Consideration: AUD$94,960.
- Purpose: Exercise of unlisted options (Classes PBTAS, PBTAW, PBTAC).
- Issue Dates: February 21–26, 2014.
Capital Structure (Post-Issue):
- Ordinary Shares Quoted on ASX: 423,105,862.
- Unlisted Options Outstanding: 19,644,352 (across various classes with exercise prices ranging from $Nil to AUD$1.12 and expiry dates between 2014 and 2019).
Financial Performance: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This document is a regulatory notice regarding a share issuance, not a financial results report.
Material Changes Versus Prior Period
Share Capital Increase: The company increased its issued share capital by 445,866 ordinary shares resulting from option exercises. These new shares rank equally with existing ordinary shares from the date of allotment.
Placement Capacity: The filing details the calculation of remaining placement capacity under ASX Listing Rules 7.1 and 7.1A:
- Rule 7.1 Remaining Capacity: 55,533,375 securities.
- Rule 7.1A Remaining Capacity: 41,620,803 securities.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary regarding business operations or financial performance.
Risks and Contingencies: No specific risks or contingencies are disclosed in this text. The document confirms compliance with Chapter 2M of the Corporations Act and states there is no "excluded information" required to be disclosed.
Dividend Policy: Unchanged.
Important Facts for Investor Verification
- Verify the identity of the registrant: The filing is for Prana Biotechnology Limited, not Altery Therapeutics Ltd.
- Confirm the total number of ordinary shares on issue is now 423,105,862 following the option exercises.
- Note the significant volume of unlisted options (19.6 million) with varying strike prices and expiry dates, which may impact future dilution.
- Review the remaining placement capacity (approx. 97 million shares combined under Rules 7.1 and 7.1A) to assess potential for future capital raises without shareholder approval.
- Check for separate financial reports (e.g., Form 20-F or ASX announcements) for actual revenue and cash flow data, as this filing does not contain them.